X
Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
(ORTI)Here is the latest stock price and chart of Ortin Labs . For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | May 26, 2017 02:45:00 PM | ||
|---|---|---|---|
| Price (Rs)17.85 | Open (Rs) 18.15 | High (Rs) 18.35 | Low (Rs) 17.80 |
| % Change2.00 | Volume 3,467 | Value (Rs) 61,886 | 52-Week H/L 26.65 / 12.50 |
| Live NSE Quotes | May 26, 2017 2:44:26 PM | ||
|---|---|---|---|
| Price (Rs)18.20 | Open (Rs) 17.60 | High (Rs) 18.20 | Low (Rs) 17.55 |
| % Change3.70 | Volume 3,770 | Value (Rs) 66,955 | 52-Week H/L 26.75 / 13.80 |
| BSE Sensex | CNX Nifty |
|
| |
After opening the day on a positive note, the Indian share markets have continued the momentum and are trading at record high levels.
Base price erosion in the US and lower Zetia sales impacts profits.
Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.
Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.
Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.
Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.
More Views on NewsThe manufacturing growth between December 2016 and March 2017 fell to 1.6 per cent as against 6.9 per cent between April and October 2016.
Underreporting of bad loans by some private sector banks casts a cloud over the sector's clean image so far.
Markets are at record highs. Fear is at record lows. How does this end? When does this end?
Asad Dossani discusses how you can double your money with derivatives.
Savings alone can't help you become rich. Investing in wealth generating investment avenues strategically is the key.
More|
| |
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | Advertise | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
